Titre : Transgènes

Transgènes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Gadolinium
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Transgènes : Questions médicales les plus fréquentes", "headline": "Transgènes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Transgènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-06", "dateModified": "2025-03-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Transgènes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Gènes", "url": "https://questionsmedicales.fr/mesh/D005796", "about": { "@type": "MedicalCondition", "name": "Gènes", "code": { "@type": "MedicalCode", "code": "D005796", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Gènes-suicide transgéniques", "alternateName": "Genes, Transgenic, Suicide", "url": "https://questionsmedicales.fr/mesh/D041722", "about": { "@type": "MedicalCondition", "name": "Gènes-suicide transgéniques", "code": { "@type": "MedicalCode", "code": "D041722", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340.825.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Transgènes", "alternateName": "Transgenes", "code": { "@type": "MedicalCode", "code": "D019076", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Xia Wang", "url": "https://questionsmedicales.fr/author/Xia%20Wang", "affiliation": { "@type": "Organization", "name": "Chongqing Engineering Research Center for Floriculture, Key Laboratory of Horticulture Science for Southern Mountainous Regions of Ministry of Education, College of Horticulture and Landscape Architecture, Southwest University, Chongqing 400715, China." } }, { "@type": "Person", "name": "Taichi Oguchi", "url": "https://questionsmedicales.fr/author/Taichi%20Oguchi", "affiliation": { "@type": "Organization", "name": "Faculty of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan." } }, { "@type": "Person", "name": "Yasir Hasan Siddique", "url": "https://questionsmedicales.fr/author/Yasir%20Hasan%20Siddique", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } }, { "@type": "Person", "name": "Falaq Naz", "url": "https://questionsmedicales.fr/author/Falaq%20Naz", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } }, { "@type": "Person", "name": "None Rahul", "url": "https://questionsmedicales.fr/author/None%20Rahul", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Gadolinium in Medical Imaging-Usefulness, Toxic Reactions and Possible Countermeasures-A Review.", "datePublished": "2022-05-24", "url": "https://questionsmedicales.fr/article/35740867", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/biom12060742" } }, { "@type": "ScholarlyArticle", "name": "Prognosis evaluation of chronic inflammatory cardiomyopathy with ring-like late gadolinium enhancement.", "datePublished": "2023-02-26", "url": "https://questionsmedicales.fr/article/36843322", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ehf2.14334" } }, { "@type": "ScholarlyArticle", "name": "Artificial Contrast: Deep Learning for Reducing Gadolinium-Based Contrast Agents in Neuroradiology.", "datePublished": "2023-02-22", "url": "https://questionsmedicales.fr/article/36822654", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/RLI.0000000000000963" } }, { "@type": "ScholarlyArticle", "name": "Radiosensitization with Gadolinium Chelate-Coated Gold Nanoparticles Prevents Aggressiveness and Invasiveness in Glioblastoma.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36660336", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/IJN.S375918" } }, { "@type": "ScholarlyArticle", "name": "Cellular toxicities of gadolinium-based contrast agents used in magnetic resonance imaging.", "datePublished": "2022-12-05", "url": "https://questionsmedicales.fr/article/36394883", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jat.4416" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Génome", "item": "https://questionsmedicales.fr/mesh/D016678" }, { "@type": "ListItem", "position": 5, "name": "Composants de génome", "item": "https://questionsmedicales.fr/mesh/D040481" }, { "@type": "ListItem", "position": 6, "name": "Gènes", "item": "https://questionsmedicales.fr/mesh/D005796" }, { "@type": "ListItem", "position": 7, "name": "Transgènes", "item": "https://questionsmedicales.fr/mesh/D019076" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Transgènes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Transgènes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Transgènes", "description": "Comment détecte-t-on des transgènes dans un organisme ?\nQuels tests sont utilisés pour analyser les transgènes ?\nLes transgènes peuvent-ils être détectés dans les aliments ?\nQuelles méthodes sont utilisées pour le diagnostic des transgènes ?\nPeut-on identifier des transgènes dans des tissus humains ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Gadolinium&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Transgènes", "description": "Quels symptômes peuvent résulter de l'expression de transgènes ?\nLes transgènes provoquent-ils des effets indésirables ?\nY a-t-il des symptômes associés aux aliments transgéniques ?\nLes transgènes peuvent-ils affecter la santé humaine ?\nQuels symptômes sont liés aux thérapies géniques ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Gadolinium&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Transgènes", "description": "Comment prévenir les risques liés aux transgènes ?\nPeut-on éviter les aliments transgéniques ?\nQuelles mesures de sécurité sont prises pour les transgènes ?\nComment sensibiliser sur les transgènes ?\nLes organismes de réglementation surveillent-ils les transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Gadolinium&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Transgènes", "description": "Comment les transgènes sont-ils utilisés en médecine ?\nLes transgènes peuvent-ils traiter des maladies ?\nQuels traitements utilisent des transgènes ?\nLes transgènes sont-ils utilisés en oncologie ?\nQuels sont les risques des traitements par transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Gadolinium&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Transgènes", "description": "Quelles complications peuvent survenir avec les transgènes ?\nLes transgènes peuvent-ils causer des maladies ?\nY a-t-il des complications environnementales liées aux transgènes ?\nComment les transgènes affectent-ils la santé publique ?\nLes transgènes peuvent-ils affecter la reproduction ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Gadolinium&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Transgènes", "description": "Quels facteurs augmentent les risques liés aux transgènes ?\nLes allergies sont-elles un facteur de risque pour les transgènes ?\nL'environnement joue-t-il un rôle dans les risques des transgènes ?\nLes antécédents médicaux influencent-ils les risques liés aux transgènes ?\nL'âge est-il un facteur de risque pour les effets des transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Gadolinium&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on des transgènes dans un organisme ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des techniques comme la PCR et le séquençage pour identifier les transgènes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour analyser les transgènes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'analyse de l'ADN par électrophorèse et la hybridation." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils être détectés dans les aliments ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests spécifiques peuvent identifier la présence de transgènes dans les aliments." } }, { "@type": "Question", "name": "Quelles méthodes sont utilisées pour le diagnostic des transgènes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent la PCR quantitative et les tests de Southern blot." } }, { "@type": "Question", "name": "Peut-on identifier des transgènes dans des tissus humains ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques comme la PCR peuvent détecter des transgènes dans des échantillons de tissus." } }, { "@type": "Question", "name": "Quels symptômes peuvent résulter de l'expression de transgènes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon le transgène, mais peuvent inclure des réactions immunitaires." } }, { "@type": "Question", "name": "Les transgènes provoquent-ils des effets indésirables ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets indésirables peuvent survenir, comme des allergies ou des toxicités." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés aux aliments transgéniques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines personnes peuvent éprouver des symptômes allergiques après consommation." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils affecter la santé humaine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que certains transgènes peuvent avoir des impacts sur la santé." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux thérapies géniques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies géniques peuvent entraîner des réactions comme de la fièvre ou des douleurs." } }, { "@type": "Question", "name": "Comment prévenir les risques liés aux transgènes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La réglementation stricte et les tests de sécurité sont essentiels pour prévenir les risques." } }, { "@type": "Question", "name": "Peut-on éviter les aliments transgéniques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en choisissant des produits bio ou en lisant les étiquettes des aliments." } }, { "@type": "Question", "name": "Quelles mesures de sécurité sont prises pour les transgènes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des études de sécurité et des évaluations environnementales sont réalisées avant leur utilisation." } }, { "@type": "Question", "name": "Comment sensibiliser sur les transgènes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des campagnes d'information et des programmes éducatifs peuvent sensibiliser le public." } }, { "@type": "Question", "name": "Les organismes de réglementation surveillent-ils les transgènes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des organismes comme l'EFSA surveillent l'utilisation et la sécurité des transgènes." } }, { "@type": "Question", "name": "Comment les transgènes sont-ils utilisés en médecine ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont utilisés pour développer des thérapies géniques pour traiter des maladies génétiques." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils traiter des maladies ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les transgènes sont utilisés pour traiter des maladies comme la fibrose kystique." } }, { "@type": "Question", "name": "Quels traitements utilisent des transgènes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements comme la thérapie génique et les vaccins génétiquement modifiés en font partie." } }, { "@type": "Question", "name": "Les transgènes sont-ils utilisés en oncologie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont utilisés pour développer des traitements ciblés contre certains cancers." } }, { "@type": "Question", "name": "Quels sont les risques des traitements par transgènes ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des réactions immunitaires et des effets secondaires imprévus." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les transgènes ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des réactions allergiques et des effets à long terme non prévus." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils causer des maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Il existe des préoccupations sur le potentiel des transgènes à induire des maladies." } }, { "@type": "Question", "name": "Y a-t-il des complications environnementales liées aux transgènes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des impacts sur la biodiversité et des effets sur les écosystèmes sont possibles." } }, { "@type": "Question", "name": "Comment les transgènes affectent-ils la santé publique ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent poser des risques pour la santé publique, nécessitant une surveillance continue." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils affecter la reproduction ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que certains transgènes pourraient avoir des effets sur la reproduction." } }, { "@type": "Question", "name": "Quels facteurs augmentent les risques liés aux transgènes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'exposition à des transgènes non réglementés et la consommation d'aliments non testés augmentent les risques." } }, { "@type": "Question", "name": "Les allergies sont-elles un facteur de risque pour les transgènes ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes allergiques peuvent avoir des réactions plus sévères aux aliments transgéniques." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle dans les risques des transgènes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conditions environnementales peuvent influencer l'impact des transgènes sur la santé." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils les risques liés aux transgènes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies auto-immunes peuvent augmenter les risques." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour les effets des transgènes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées peuvent être plus sensibles aux effets des transgènes." } } ] } ] }

Sources (966 au total)

Prognosis evaluation of chronic inflammatory cardiomyopathy with ring-like late gadolinium enhancement.

Ring-like late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging is a special LGE pattern in patients with chronic inflammatory cardiomyopathy (infl-CMP), which is associated wi... A total of 319 consecutive patients with clinically suspected myocarditis were retrospectively identified. Forty-seven patients with ring-like LGE on CMR who diagnosed as infl-CMP, and 72 patients wit... For infl-CMP patients with ring-like LGE on CMR, low BMI and RVCI were associated with a poor prognosis. LV-PCS...

Radiosensitization with Gadolinium Chelate-Coated Gold Nanoparticles Prevents Aggressiveness and Invasiveness in Glioblastoma.

This study aimed to evaluate the radiosensitizing potential of Au@DTDTPA(Gd) nanoparticles when combined with conventional external X-ray irradiation (RT) to treat GBM.... Complementary biological models based on U87 spheroids including conventional 3D invasion assay, organotypic brain slice cultures, chronic cranial window model were implemented to investigate the impa... In vitro clonogenic assays showed that Au@DTDTPA(Gd) nanoparticles exerted a radiosensitizing effect on U87 cells, and in vivo experiments suggested a benefit of the combined treatment "RT 2×5 Gy + Au... Combining Au@DTDTPA(Gd) nanoparticles and X-ray radiotherapy appears as an attractive therapeutic strategy to decrease number, viability and aggressiveness of tumor cells that escape and can invade th...

Evaluation of late gadolinium enhancement cardiac MRI using deep learning reconstruction.

Deep learning (DL)-based methods have been used to improve the imaging quality of magnetic resonance imaging (MRI) by denoising.... To assess the effects of DL-based MR reconstruction (DLR) method on late gadolinium enhancement (LGE) image quality.... A total of 85 patients who underwent cardiovascular magnetic resonance (CMR) examination, including LGE imaging using conventional construction and DLR with varying levels of noise reduction (NR) leve... Both MLGE and PSLGE with DLR at 50% and 75% noise reduction levels received significantly higher scores than conventional imaging for overall imaging quality (all... DLR reduced image noise while improving image contrast and sharpness in the cardiovascular LGE imaging....

Utility of Gadolinium-Based Contrast in Initial Evaluation of Seizures in Children Presenting Emergently.

The frequency and utility of gadolinium in evaluation of acute pediatric seizure presentation is not well known. The purpose of this study was to assess the utility of gadolinium-based contrast agents... We identified consecutive pediatric patients with new-onset seizures from October 1, 2016, to September 30, 2021, who presented to the emergency department and/or were admitted to the inpatient unit a... A total of 1884 patients were identified for inclusion. Five hundred twenty-four (28%) patients had potential epileptogenic findings on brain MR imaging, while 1153 (61%) patients had studies with nor... Gadolinium contrast is of limited additive benefit in the imaging of patients with an acute onset of pediatric seizures in most instances....

Prospective T1 mapping to assess gadolinium retention in brain after intrathecal gadobutrol.

A possible pathway behind gadolinium retention in brain is leakage of contrast agents from blood to cerebrospinal fluid and entry into brain along perivascular (glymphatic) pathways. The object of thi... We prospectively applied standardized T1 mapping of the brain before and 4 weeks after intrathecal administration of 0.5 mmol gadobutrol in patients under work-up of cerebrospinal fluid circulation di... In a cohort of 76 participants (mean age 47.2 years ± 17.9 [standard deviation], 47 women), T1 relaxation times remained unchanged in cerebral cortex and basal ganglia 4 weeks after intrathecal gadobu... Gadolinium retention was not detected in the cerebral hemispheres 4 weeks after an intrathecal dose of 0.5 mmol gadobutrol, implying that presence of contrast agents in cerebrospinal fluid is of minor...

Sex-based differences in late gadolinium enhancement among patients with acute myocarditis.

The aims of our study were to investigate the sex differences in late gadolinium enhancement (LGE) using cardiovascular magnetic resonance (CMR) in a single-centre cohort of consecutive patients with ... This retrospective study performed CMR scans in 135 consecutive patients with AM that met the Lake Louise criteria. On CMR, LV ventricular strain functions were performed on conventional cine SSFP seq... There was no difference in age (age 42.51 ± 19.64 years vs 40.92 ± 19.94 years; p = 0.74) and cardiovascular risk profile between women and men. Despite similar comorbidities, women were more like to ... This is the first study reporting sex differences in LGE localization in AM. Women have more septal LGE involvement independent of age, cardiovascular risk factors, and CMR parameters. These findings ...